Abstract
Recent research efforts provided compelling evidence of genome-wide DNA methylation alterations in aging and age-related disease. It is currently well established that DNA methylation biomarkers can determine biological age of any tissue across the entire human lifespan, even during development. There is growing evidence suggesting epigenetic age acceleration to be strongly linked to common diseases or occurring in response to various environmental factors. DNA methylation based clocks are proposed as biomarkers of early disease risk as well as predictors of life expectancy and mortality. In this review, we will summarize key advances in epigenetic clocks and their potential application in precision health. We will also provide an overview of progresses in epigenetic biomarker discovery in Alzheimer’s, type 2 diabetes, and cardiovascular disease. Furthermore, we will highlight the importance of prospective study designs to identify and confirm epigenetic biomarkers of disease.
| Original language | English |
|---|---|
| Article number | 171 |
| Journal | Frontiers in Genetics |
| Volume | 11 |
| DOIs | |
| Publication status | Published - 10 Mar 2020 |
Keywords
- Alzheimer’s disease
- DNA methylation
- aging
- biomarkers
- cardiovascular diseases
- diabetes
- epigenetic clocks